- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04452877
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
An Open-Label, Single-arm Study to Evaluate the Safety and Efficacy of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single arm, open label, multicenter phase II study evaluating the efficacy and safety of dabrafenib in combination with trametinib in Chinese participant with BRAF V600E mutation positive AJCC v8 stage IV Non-Small Cell Lung Cancer.
Participants with stage IV BRAF V600E mutant Non-Small Cell Lung Cancer confirmed by local qualified assay (approved by China health authorities) will be enrolled in this study. Central confirmation testing for BRAF V600E will be performed. This study will enroll participants:
- who have not received any prior systemic anti-cancer therapy for metastatic disease (i.e. dabrafenib/trametinib will be the 1st line treatment for metastatic disease)
- who have relapsed or progressed on at least one prior platinum based chemotherapy prior to enrollment but cannot have received more than 3 prior systemic therapies for metastatic disease (i.e. dabrafenib/trametinib will be no less than second line treatment for metastatic disease).
All participants must not have been previously exposed to a BRAF or MEK inhibitor. Participants will receive the recommended dose of both drugs (dabrafenib 150 mg twice daily and trametinib 2 mg once daily).
The primary endpoint for the study is Overall Response Rate, as determined by central independent review, using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Approximately 40 Chinese patients over 18 years old will be enrolled in this study and will receive dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) combination therapy until disease progression by RECIST 1.1, unacceptable toxicity, start of a new antineoplastic therapy, pregnancy, withdrawal of consent, lost to follow-up, physician's decision, death, or if study is terminated by the sponsor. Doses of study treatment may be modified and/or interrupted for management of toxicities associated with study treatment.
Treatment beyond disease progression per RECIST is allowed if protocol specific criteria are met. The tumor assessments will be performed every 6 weeks until Week 36, and every 12 weeks thereafter until disease progression, death, lost of follow-up, or withdrawal of consent. Survival and new anti-cancer therapy follow-up will continue until study completion.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
Study Locations
-
-
-
Beijing, China, 100036
- Novartis Investigative Site
-
Changsha, China, 410013
- Novartis Investigative Site
-
Guangzhou, China, 510060
- Novartis Investigative Site
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Novartis Investigative Site
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Novartis Investigative Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Novartis Investigative Site
-
Hangzhou, Zhejiang, China, 310022
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of Stage IV NSCLC (according to AJCC 8th edition) that is BRAF V600E mutation-positive by local test result from a qualified assay (NMPA and/or MOH-approved)
Previously treated or untreated for metastatic NSCLC:
- Participants previously treated should have received no more than 3 prior systemic therapies for metastatic disease, with at least one prior platinum based chemotherapy, and should have documented disease progression on a prior treatment regimen (i.e. RECIST 1.1)
- Participants who have received prior therapy with checkpoint inhibitor therapy (i.e. anti-PD-1/PD-L1) must have had objective evidence of disease progression (i.e. RECIST v1.1) while on or after this therapy prior to enrollment.
- Participants with EGFR or ALK mutation who have previously received therapy with EGFR or ALK inhibitor(s) respectively are eligible
- Measurable disease per RECIST v1.1
- Anticipated life expectancy of at least 3 months
- ECOG performance status ≤ 2.
- Adequate bone marrow and organ function as defined by the following laboratory values without continuous supportive treatment (such as blood transfusion, coagulation factors and/or platelet infusion, or red/white blood cell growth factor administration) as assessed by local laboratory for eligibility: Hemoglobin ≥ 9 g/dL; Absolute neutrophil count ≥ 1.5 × 109/L; Platelets ≥ 100 × 109/L; PT/INR and PTT ≤ 1.5 x ULN; Serum creatinine < 1.5 mg/dL; Total bilirubin ≤ 1.5 × ULN (upper limit of normal) except for participantss with Gilbert's syndrome who may only be included if the total bilirubin is ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN; AST and ALT ≤ 2.5 × ULN, except for participant with liver metastasis, who may only be included if AST/ALT ≤ 5.0 × ULN Albumin ≥ 2.5 g/dL
- Left ventricular ejection fraction (LVEF) ≥ lower limit of institutional normal (LLN) as assessed by ECHO or MUGA scan
Exclusion Criteria:
- Participants with brain or leptomeningeal metastases are excluded if their these metastases are: symptomatic or treated but not clinically and radiographically stable 3 weeks after local therapy or asymptomatic and untreated but >1 cm in the longest dimension
- Previous treatment with a BRAF inhibitor or a MEK inhibitor
- All prior anti-cancer treatment-related toxicities must be Grade 2 or less according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.03; NCI, 2009) at the time of enrollment
- Prior anti-cancer treatment within the last 2 weeks, and prior treatment with immune checkpoint inhibitors within 4 weeks preceding the first dose of the study treatment.
- Current use of a prohibited medication
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO).
- Participants with known history for testing positive for Human Immunodeficiency Virus (HIV)
- History of another malignancy <3 years prior to starting study treatment or any malignancy with confirmed activating RAS-mutation.
- Cardiac or cardiac repolarization abnormality
- A history or current evidence/risk of retinal vein occlusion (RVO) or serous retinopathy
- History or current interstitial lung disease or non-infectious pneumonitis
- Any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that, in the opinion of the investigator, could interfere with the participant's safety, obtaining informed consent, or compliance with study procedures
- Pregnant or nursing (lactating) women.
- Sexually active males (including those that have had a vasectomy) must use a condom during intercourse and should not father a child during this period. The amount of time a patient must use a condom for 16 weeks post treatment discontinuation
- Participants with active Hepatitis B infection (HbsAg positive)
- Participants with positive test for hepatitis C ribonucleic acid (HCV RNA)
- Concurrent participation in other clinical trials using experimental therapies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dabrafenib in combination with trametinib
Dabrafenib 150 mg twice daily, trametinib 2 mg once daily
|
Dabrafenib will be provided by the sponsor to the investigative site or supplied locally as commercially available.
Dabrafenib will be administered orally twice daily (150 mg BID) for Days 1-21 of a 21-day cycle.
Other Names:
Trametinib will be provided by the sponsor to the investigative site or supplied locally as commercially available.
Trametinib will be administered orally once daily (2 mg QD) for Days 1-21 of a 21-day cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR), central independent review assessed by RECIST v1.1
Time Frame: From baseline until disease progression, death, lost to follow-up or withdrawal of consent, whichever occurs first, assessed up to approximately 12 months from treatment initiation
|
Overall Response Rate is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) by central independent review as per RECIST v1.1 criteria
|
From baseline until disease progression, death, lost to follow-up or withdrawal of consent, whichever occurs first, assessed up to approximately 12 months from treatment initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR), investigator assessed by RECIST v1.1
Time Frame: From baseline until disease progression, death, lost to follow-up or withdrawal of consent, whichever occurs first, assessed up to approximately 12 months from treatment initiation
|
ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) by investigator assessment as per RECIST 1.1 criteria
|
From baseline until disease progression, death, lost to follow-up or withdrawal of consent, whichever occurs first, assessed up to approximately 12 months from treatment initiation
|
Progression Free Survival (PFS), investigator assessed by RECIST v1.1
Time Frame: From baseline until disease progression or death due to any cause, whichever occurs first, assessed up to approximately 12 months from treatment initiation
|
PFS is defined as the interval between first dose and the earliest date of disease progression or death due to any cause.
PFS will be assessed via local review according to RECIST 1.1.
|
From baseline until disease progression or death due to any cause, whichever occurs first, assessed up to approximately 12 months from treatment initiation
|
Duration of Response (DoR), investigator assessed by RECIST v1.1
Time Frame: From first documented response until first documented progression or death due to any cause, whichever occurs first, assessed up to approximately 12 months from treatment initiation
|
DoR is defined for the subset of participants with confirmed CR or PR, as the time from first documented evidence of CR or PR until time of first documented disease progression according to RECIST v1.1 per local review or death due to any cause
|
From first documented response until first documented progression or death due to any cause, whichever occurs first, assessed up to approximately 12 months from treatment initiation
|
Overall Survival (OS)
Time Frame: From baseline until death due to any cause, assessed up to approximately 33 months from treatment initiation
|
OS is defined as the time from first dose until death due to any cause
|
From baseline until death due to any cause, assessed up to approximately 33 months from treatment initiation
|
Trough concentration of dabrafenib
Time Frame: Pre-dose sample at visits week 3, 6 and 12
|
Mean trough concentration will be calculated at each timepoint
|
Pre-dose sample at visits week 3, 6 and 12
|
Trough concentration of dabrafenib metabolites (hydroxy-dabrafenib, and desmethyl-dabrafenib)
Time Frame: Pre-dose sample at visits week 3, 6 and 12
|
Mean trough concentration will be calculated at each timepoint
|
Pre-dose sample at visits week 3, 6 and 12
|
Trough concentration of trametinib
Time Frame: Pre-dose sample at visits week 3, 6 and 12
|
Mean trough concentration will be calculated at each timepoint
|
Pre-dose sample at visits week 3, 6 and 12
|
Mean change from baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) score
Time Frame: From baseline, every 3 weeks until end of treatment (up to approximately 32 months after treatment initiation)
|
EQ-5D-5L is a standardized measure to assess the overall health-related quality of life in patients.
|
From baseline, every 3 weeks until end of treatment (up to approximately 32 months after treatment initiation)
|
Mean change from baseline in the European Organization for Research and Treatment of Cancer core quality of life questionnaire (EORTC QLQ-C30) score
Time Frame: From baseline, every 3 weeks until end of treatment (up to approximately 32 months after treatment initiation)
|
EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients.
|
From baseline, every 3 weeks until end of treatment (up to approximately 32 months after treatment initiation)
|
Mean Change from Baseline in the European Organization for Research and Treatment of Cancer lung cancer specific module (EORTC QLQ-LC13) score
Time Frame: From baseline, every 3 weeks until end of treatment (up to approximately 32 months after treatment initiation)
|
EORTC QLQ-LC13 is a 13-item lung cancer specific questionnaire.
|
From baseline, every 3 weeks until end of treatment (up to approximately 32 months after treatment initiation)
|
Number of patients with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: From baseline until end of study, assessed up to approximately 33 months from treatment initiation
|
Safety profile of dabrafenib in combination with trametinib.
Incidence of Adverse Events and Serious Adverse events, including abnormal laboratory values or test results.
|
From baseline until end of study, assessed up to approximately 33 months from treatment initiation
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Trametinib
- Dabrafenib
Other Study ID Numbers
- CDRB436ECN01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non-Small-Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on Dabrafenib
-
Novartis PharmaceuticalsTerminated
-
Novartis PharmaceuticalsCompleted
-
Universitair Ziekenhuis BrusselCompleted
-
UNC Lineberger Comprehensive Cancer CenterGlaxoSmithKlineCompletedUnresectable Melanoma | Stage IV Melanoma | Stage III Melanoma | BRAF Mutant MelanomaUnited States
-
University Medical Center GroningenTerminated
-
GlaxoSmithKlineCompleted
-
Fondazione Melanoma OnlusWithdrawn
-
Novartis PharmaceuticalsRecruitingBRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid TumorJapan
-
Novartis PharmaceuticalsCompletedMalignant MelanomaPortugal
-
Spirita Oncology, LLCUniversity of ArizonaTerminatedBrain Metastases | Malignant MelanomaUnited States